Cargando…

Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Despite the existence of various therapeutic options, NSCLC is still a major health concern due to its aggressive nature and high mutation rate. Consequently, HER3 has been selected as a target protein along with EGFR because...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dera, Ayed A., Zaib, Sumera, Areeba, Hussain, Nadia, Rana, Nehal, Javed, Hira, Khan, Imtiaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304665/ https://www.ncbi.nlm.nih.gov/pubmed/37375404 http://dx.doi.org/10.3390/molecules28124850

Ejemplares similares

Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy
por: Zaib, Sumera, et al.
Publicado: (2023)

Designing multi-epitope monkeypox virus-specific vaccine using immunoinformatics approach
por: Zaib, Sumera, et al.
Publicado: (2023)

Bioinformatics approach for the construction of multiple epitope vaccine against omicron variant of SARS-CoV-2
por: Zaib, Sumera, et al.
Publicado: (2022)

Ultrasound-Assisted Synthesis of Piperidinyl-Quinoline Acylhydrazones as New Anti-Alzheimer’s Agents: Assessment of Cholinesterase Inhibitory Profile, Molecular Docking Analysis, and Drug-like Properties
por: Munir, Rubina, et al.
Publicado: (2023)

Designing Next-Generation Drug-like Molecules for Medicinal Applications
por: Khan, Imtiaz, et al.
Publicado: (2023)

Microwave-Assisted Synthesis of (Piperidin-1-yl)quinolin-3-yl)methylene)hydrazinecarbothioamides as Potent Inhibitors of Cholinesterases: A Biochemical and In Silico Approach
por: Munir, Rubina, et al.
Publicado: (2021)

Synthesis, In Vitro Anti-Microbial Analysis and Molecular Docking Study of Aliphatic Hydrazide-Based Benzene Sulphonamide Derivatives as Potent Inhibitors of α-Glucosidase and Urease
por: Khan, Shoaib, et al.
Publicado: (2022)

New Triazinoindole Bearing Benzimidazole/Benzoxazole Hybrids Analogs as Potent Inhibitors of Urease: Synthesis, In Vitro Analysis and Molecular Docking Studies
por: Mumtaz, Sundas, et al.
Publicado: (2022)

Discovery of Potent Dual EGFR/HER2 Inhibitors Based on Thiophene Scaffold Targeting H1299 Lung Cancer Cell Line
por: Elrayess, Ranza, et al.
Publicado: (2020)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
por: Jänne, Pasi A., et al.
Publicado: (2022)

Identification of Potent EGFR Inhibitors from TCM Database@Taiwan
por: Yang, Shun-Chieh, et al.
Publicado: (2011)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
Publicado: (2022)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
por: Fan, Fushun, et al.
Publicado: (2020)

Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines
por: Son, Seohyun, et al.
Publicado: (2023)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
por: Li, Meng, et al.
Publicado: (2021)

Machine Learning-Based Approach to Developing Potent EGFR Inhibitors for Breast Cancer—Design, Synthesis, and In Vitro Evaluation
por: Nada, Hossam, et al.
Publicado: (2023)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
por: Wang, Xiaochun, et al.
Publicado: (2016)

Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
por: Li, Yanxia, et al.
Publicado: (2016)

Inhibition of Aldose Reductase by Ginsenoside Derivatives via a Specific Structure Activity Relationship with Kinetics Mechanism and Molecular Docking Study
por: Ali, Md Yousof, et al.
Publicado: (2022)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

Molecular docking and pharmacokinetic evaluation of natural compounds as targeted inhibitors against Crz1 protein in Rhizoctonia solani
por: Malik, Ajit, et al.
Publicado: (2019)

Molecular docking and pharmacokinetic evaluation of natural compounds as targeted inhibitors against Crz1 protein in Rhizoctonia solani
por: Malik, Arshi, et al.
Publicado: (2021)

Preparation, Characterization, and Pharmacological Investigation of Withaferin-A Loaded Nanosponges for Cancer Therapy; In Vitro, In Vivo and Molecular Docking Studies
por: Shah, Hamid Saeed, et al.
Publicado: (2021)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors
por: Ghorab, Mostafa M., et al.
Publicado: (2017)

Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers
por: Soliman, Aiten M., et al.
Publicado: (2019)

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
por: Bosch-Vilaró, Albert, et al.
Publicado: (2016)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy
por: Song, Won-Min, et al.
Publicado: (2023)

Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors
por: Tu, Yuanbiao, et al.
Publicado: (2018)

Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor
por: He, Pengxing, et al.
Publicado: (2019)

HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285
por: Takagi, Shinji, et al.
Publicado: (2014)

Design, Synthesis, In Silico Testing, and In Vitro Evaluation of Thiazolidinone-Based Benzothiazole Derivatives as Inhibitors of α-Amylase and α-Glucosidase
por: Khan, Shoaib, et al.
Publicado: (2022)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_5ve1v4d6lom9o27j5iknqvmhlk